#China #Minghui Pharmaceutical #Thyroid Eye Disease #MHB018A #Shanghai, Hangzhou

Minghui Pharmaceutical Highlights Phase I/II Results for MHB018A

Minghui Pharmaceutical, a leading biopharmaceutical firm based in both Shanghai and Hangzhou, recently presented the promising results of its Phase I/II clinical trials for MHB018A, a groundbreaking subcutaneous anti-IGF-1R antibody designed to tackle thyroid eye disease (TED). This highly anticipated presentation took place during the ENDO 2026 conference, hosted by the Endocrine Society in Chicago, USA.

Clinical Efficacy of MHB018A

The data showcased at the conference revealed that MHB018A demonstrated impressive clinical activity in both active thyroid eye disease (aTED) as well as chronic thyroid eye disease (cTED). At a dosage of 450 mg given every four weeks, the results spoke volumes about the antibody's effectiveness. Specifically, an 81% proptosis response was observed in patients with active TED at twelve weeks, along with a significant reduction in both proptosis and diplopia. Even in chronic cases evaluated at the twenty-four-week mark, the 76% response rate highlights MHB018A's potential as a formidable treatment option.

The overall responses were also noteworthy. In the aTED group, 78% of participants showed significant improvement, with 85% experiencing relief from diplopia and 59% achieving complete resolution of the symptom. For the cTED group, improvements in proptosis and diplopia further emphasized the drug's effectiveness across varied patient needs.

Safety Profile

Moreover, safety did not take a back seat in the study; MHB018A was well tolerated by the 98 patients treated. Most adverse events were mild, correlating with the anticipated effects of IGF-1R inhibition. Remarkably, all hearing-related adverse events were classified as Grade 1, with no instances of severe or permanent damage, showcasing MHB018A's excellent safety profile which is crucial for patient acceptance and long-term usage.

Future Prospects

Dr. Guoqing Cao, the CEO of Minghui, expressed satisfaction with the presentation and test results. He stated, "MHB018A, as a novel antibody targeting IGF-1R, is designed to completely inhibit both IGF-1 and IGF-2 mediated signaling pathways. The data we unveiled demonstrate not only outstanding clinical activity in both active and chronic TED cases but also solid patient safety."

The potential is clear as MHB018A is currently undergoing Phase III trials in China, with expectations for topline results to emerge in the third quarter of 2026. Additionally, efforts towards global Phase III clinical trials are already underway, with plans for first patient enrollment scheduled for the last quarter of 2026. The aim is to address unmet needs in patient populations suffering from thyroid eye disease across the world.

Conclusion

The compelling results of the clinical trials position MHB018A not only as a competitive option within the anti-IGF-1R therapy landscape but also as a candidate with the potential to significantly enhance the quality of life for those afflicted by thyroid eye disease. As preparations for wider clinical application continue, stakeholder interest and patient hope ride high, underscoring the transformative potential of modern biopharmaceutical innovations like MHB018A.